Abstract Library

#4649 Claudin 18.2 overexpression in gastric neuroendocrine tumours

Introduction: Claudin 18.2, is a tissue biomarker physiologically expressed in both healthy gastric mucosa and gastric adenocarcinoma which represents a novel therapeutic target advanced gastric cancer. Various other cancers showed some overexpression of claudin 18.2 opening potential opportunities to agnostic targeted therapy. However, data about claudin 18.2 expression in NENs are poor with only an Eastern study showing higher rate of claudin 18.2 positivity in GEP-NENs, mainly from gastric primary site (27.8%).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Lobrano R, Pisa E, Benini L, Spada F,

Keywords: claudin, gastric NET, biomarker, Neuroendocrine tumour,

#4509 Epidemiological characteristics and prognosis analysis of gastric cancer (GC) with neuroendocrine differentiation (NED)

Introduction: GC with NED exhibits distinct biological characteristics, yet research on its clinical features and prognosis remains limited.

Conference:

Presenting Author: Zhang J

Authors: Huang Z, Li J, Wang C, Shen Y, Rao S,

Keywords: gastric cancer, neuroendocrine differentiation, Epidemiological characteristics, prognosis,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4414 Impact of chromogranin A expression on clinicopathological characteristics and prognosis in patients with gastrointestinal tumours exhibiting neuroendocrine differentiation

Introduction: Pathological diagnosis of neuroendocrine differentiation (NED) relies on histomorphological assessment and specific markers, including chromogranin A (CgA) and synaptophysin (Syn). Previous studies indicate that tumours with a high proportion of CgA (+) exhibit increased malignancy and aggressiveness in neuroendocrine tumours, suggesting that CgA may serve as a prognostic marker.

Conference:

Presenting Author: Liang T

Authors: Wang W, Jiang K, Liu X, Zhao L, Yu Z,

Keywords: neuroendocrine differentiation, gastric cancer, colorectal cancer, chromogranin A,

#4108 Clinical and epidemiological profile of neuroendocrine differentiation – A hospital-based retrospective study

Introduction: Global research on neuroendocrine differentiation (NED) in carcinomas remains limited, despite its distinct clinical features, disease progression, pathology, treatment outcomes, and poor prognosis. At the 2023 ENETS Conference, we presented our findings on NED in gastric cancer and colorectal cancer. However, more studies are essential to better comprehend NED's clinical and epidemiological aspects.

Conference:

Presenting Author:

Authors: Wen Y, Shi S,

Keywords: Neuroendocrine differentiation, breast cancer, lung cancer, esophageal cancer, prostate cancer,